Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $3.2 million.

  • Keros Therapeutics' Cash from Operations rose 11065.25% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.8 million, marking a year-over-year increase of 16327.61%. This contributed to the annual value of -$160.9 million for FY2024, which is 2920.37% down from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Cash from Operations is $3.2 million, which was up 11065.25% from -$29.6 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Cash from Operations peaked at $161.2 million during Q1 2025, and registered a low of -$46.0 million during Q4 2024.
  • Its 5-year average for Cash from Operations is -$14.9 million, with a median of -$24.6 million in 2022.
  • As far as peak fluctuations go, Keros Therapeutics' Cash from Operations plummeted by 229908.9% in 2023, and later skyrocketed by 46169.43% in 2025.
  • Keros Therapeutics' Cash from Operations (Quarter) stood at -$19.6 million in 2021, then fell by 9.6% to -$21.4 million in 2022, then decreased by 18.73% to -$25.5 million in 2023, then tumbled by 80.71% to -$46.0 million in 2024, then soared by 107.06% to $3.2 million in 2025.
  • Its Cash from Operations was $3.2 million in Q3 2025, compared to -$29.6 million in Q2 2025 and $161.2 million in Q1 2025.